Benjamin Carr, Ph.D. 👨🏻💻🧬One #LSD trip shown to provide rapid and lasting reduction in #anxiety, #FDA designates "breakthrough therapy"
Single dose of #MM120 led to 48% rate of remission from generalized anxiety disorder at 12 weeks following drug's administration
MM120 drug also significantly improved clinical signs of generalized anxiety disorder for 65% of patients within three months, according to results of the #phase2b trial designed to test dosage levels, the company said. https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html #mentalhealth
Single dose of #MM120 led to 48% rate of remission from generalized anxiety disorder at 12 weeks following drug's administration
MM120 drug also significantly improved clinical signs of generalized anxiety disorder for 65% of patients within three months, according to results of the #phase2b trial designed to test dosage levels, the company said. https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html #mentalhealth
